Calico taps Mabwell’s anti-ageing antibody in $596m licensing deal
FierceBiotech - 26-Jul-2025Alphabet's Calico licenses IL-11 drug to target age-related diseases beyond China
Join the club for FREE to access the whole archive and other member benefits.
Combating aging and associated diseases. An Alphabet (Google) subsidiary.
Founded in 2013 by Bill Maris.
Calico is a research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.
Chief scientist, David Botstein, retired late 2022.
Visit website: https://www.calicolabs.com/
Details last updated 04-Feb-2019
Alphabet's Calico licenses IL-11 drug to target age-related diseases beyond China
AI startup decodes live cell behaviour using simple imaging and machine learning
Nellie is free, easy to use, and performs better than other tracking methods
PERISCOPE links genes to cell structure, revealing new insights
Fosigotifator and DNL343 miss key goals, sparking calls for deeper analysis and longer studies
Global dynamic model of transcriptional regulation in budding yeast